Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.

Publisher Website
Google Scholar
Abstract
Of 76 patients, 61 entered on a prospective randomized trial of neocarzinostatin (NCZ) vs. m-AMSA [4''(9-acridinylamine)-methanesulfon-m-anisidide] or doxorubicin were eligible for analysis. Among these 61 patients at least 1 episode of severe toxicity was documented in 39% of patients on NCZ and 58% on m-AMSA. Of the 61 patients, 51 were previously untreated with chemotherapy. Among these 51 patients objective response was documented in 2 of 25 patients treated with NCZ, none of 17 treated with m-AMSA and 1 of 9 treated with doxorubicin. Among previously untreated North American and European (NA/E) patients the median survival times were: NCZ 11 wk and m-AMSA 12 wk. The data on South African (SA) patients with similar entrance criteria entered on earlier Eastern Cooperative Oncology Group trials were analyzed with that from the randomized trial and show that for SA patients the median survival times were: NCZ, 11 wk (31 patients); m-AMSA, 13 wk (33 patients); and doxorubicin, 15 wk (29 patients).